{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:29Z","timestamp":1791994589048,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81521005"],"award-info":[{"award-number":["81521005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81925035"],"award-info":[{"award-number":["81925035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82050410361"],"award-info":[{"award-number":["82050410361"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2019PB0076"],"award-info":[{"award-number":["2019PB0076"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2020PB0094"],"award-info":[{"award-number":["2020PB0094"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.apsb.2021.09.022","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T08:52:07Z","timestamp":1632991927000},"page":"2057-2073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Remodeling \u201ccold\u201d tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona"],"prefix":"10.1016","volume":"12","author":[{"given":"Yang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuge","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahtiyor","family":"Muhitdinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akmal","family":"Asrorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8915","authenticated-orcid":false,"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.09.022_bib1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omto.2019.04.008","article-title":"Dual regulatory mechanisms of expression and mutation involving metabolism-related genes FDFT1 and UQCR5 during CLM","volume":"14","author":"Ma","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apsb.2021.09.022_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccell.2019.08.003","article-title":"Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis","volume":"36","author":"Jackstadt","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.09.022_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc.2016.126","article-title":"Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2021.09.022_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.09.022_bib5","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2217\/imt-2017-0134","article-title":"Modulation of antitumor immunity with histone deacetylase inhibitors","volume":"9","author":"Mccaw","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.apsb.2021.09.022_bib6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2021.09.022_bib7","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.2174\/0929867324666170801102124","article-title":"Histone deacetylase inhibitors in tumor immunotherapy","volume":"26","author":"Zhao","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2021.09.022_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4161\/cc.3.6.927","article-title":"Histone-deacetylase inhibitors for the treatment of cancer","volume":"3","author":"Lindemann","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.apsb.2021.09.022_bib9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fcell.2020.00400","article-title":"Nanotechnology-based histone deacetylase inhibitors for cancer therapy","volume":"8","author":"Tu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2021.09.022_bib10","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1021\/acs.nanolett.7b03756","article-title":"Reprogramming tumor-associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codelivery of Gefitinib\/Vorinostat","volume":"17","author":"Peng","year":"2017","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2021.09.022_bib11","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fphar.2018.00612","article-title":"Trichostatin a protects dendritic cells against oxygen-glucose deprivation via the SRSF3\/PKM2\/glycolytic pathway","volume":"9","author":"Jiang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2021.09.022_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fgene.2018.00427","article-title":"Metabolism and epigenetic interplay in cancer: regulation and putative therapeutic targets","volume":"9","author":"Miranda-Gon\u00e7alves","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.apsb.2021.09.022_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","article-title":"The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity","volume":"23","author":"Woods","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.apsb.2021.09.022_bib14","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2021.09.022_bib15","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2021.09.022_bib16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/2326-6066.CIR-18-0077","article-title":"BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non\u2013small cell lung cancer","volume":"6","author":"Adeegbe","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2021.09.022_bib17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41401-020-00570-8","article-title":"Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan\/JQ1 for chemo-immunotherapy","volume":"42","author":"He","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2021.09.022_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2021.09.022_bib19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fmicb.2020.00814","article-title":"Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway","volume":"11","author":"Xu","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2021.09.022_bib20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.09.022_bib21","doi-asserted-by":"crossref","first-page":"119097","DOI":"10.1016\/j.ijpharm.2020.119097","article-title":"Lactoferrin\/hyaluronic acid double-coated lignosulfonate nanoparticles of quinacrine as a controlled release biodegradable nanomedicine targeting pancreatic cancer","volume":"578","author":"Etman","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.09.022_bib22","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1021\/acs.nanolett.9b00021","article-title":"Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of Shikonin\/JQ1","volume":"19","author":"Wang","year":"2019","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2021.09.022_bib23","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","article-title":"Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy","volume":"10","author":"Zhu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.09.022_bib24","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/IJN.S129300","article-title":"Protein corona: a new approach for nanomedicine design","volume":"12","author":"Nguyen","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.apsb.2021.09.022_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fgene.2018.00427","article-title":"Metabolism and epigenetic interplay in cancer: regulation and putative therapeutic targets","volume":"9","author":"Miranda-Goncalves","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.apsb.2021.09.022_bib26","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1172\/JCI129049","article-title":"HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models","volume":"130","author":"Nguyen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2021.09.022_bib27","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1016\/j.celrep.2017.11.052","article-title":"Neutrophils and snail orchestrate the establishment of a pro-tumor microenvironment in lung cancer","volume":"21","author":"Faget","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2021.09.022_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7150\/thno.27246","article-title":"Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin beta3\/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery","volume":"9","author":"Jin","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2021.09.022_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201802372","article-title":"Remodeling tumor-associated macrophages and neovascularization overcomes EGFR(T790M)-associated drug resistance by PD-L1 nanobody-mediated codelivery","volume":"14","author":"Yin","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.apsb.2021.09.022_bib30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.09.022_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.33","article-title":"Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan","volume":"7","author":"Chen","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2021.09.022_bib32","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","article-title":"Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines","volume":"112","author":"Buglio","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2021.09.022_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1039\/C8SM02189A","article-title":"Interaction of functionalized nanoparticles with serum proteins and its impact on colloidal stability and cargo leaching","volume":"15","author":"Abstiens","year":"2019","journal-title":"Soft Matter"},{"key":"10.1016\/j.apsb.2021.09.022_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.nano.2014.11.003","article-title":"Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines","volume":"11","author":"Caracciolo","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.09.022_bib35","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cbic.201800201","article-title":"Roles of albumin-binding proteins in cancer progression and biomimetic targeted drug delivery","volume":"19","author":"Zhao","year":"2018","journal-title":"ChemBioChem"},{"key":"10.1016\/j.apsb.2021.09.022_bib36","doi-asserted-by":"crossref","first-page":"1700403","DOI":"10.1002\/adfm.201700403","article-title":"Dual-targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug-resistant cancer therapy","volume":"27","author":"Zhao","year":"2017","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2021.09.022_bib37","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1039\/C7SC04853J","article-title":"Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy","volume":"9","author":"Zhao","year":"2018","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2021.09.022_bib38","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1152\/ajplung.2001.281.6.L1512","article-title":"Albumin uptake and transcytosis in endothelial cells in\u00a0vivo induced by albumin-binding protein","volume":"281","author":"Vogel","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.apsb.2021.09.022_bib39","doi-asserted-by":"crossref","first-page":"1700403","DOI":"10.1002\/adfm.201700403","article-title":"Dual-targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug-resistant cancer therapy","volume":"27","author":"Zhao","year":"2017","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2021.09.022_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2021.09.022_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1014774","article-title":"Lactic acid polarizes macrophages to a tumor-promoting state","volume":"5","author":"Colegio","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.apsb.2021.09.022_bib42","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/cells8070761","article-title":"Tumor angiogenic inhibition triggered necrosis (TAITN) in oral cancer","volume":"8","author":"Yoshida","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2021.09.022_bib43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2021.09.022_bib44","first-page":"447","article-title":"Comprehensive analysis of somatic mutations in colorectal cancer with peritoneal metastasis","volume":"33","author":"Lee","year":"2019","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.apsb.2021.09.022_bib45","doi-asserted-by":"crossref","first-page":"120187","DOI":"10.1016\/j.biomaterials.2020.120187","article-title":"Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery","volume":"255","author":"Chen","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.09.022_bib46","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/fon.10.100","article-title":"Intraperitoneal therapy for peritoneal cancer","volume":"6","author":"Lu","year":"2010","journal-title":"Future Oncol"},{"key":"10.1016\/j.apsb.2021.09.022_bib47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s42255-020-0195-8","article-title":"Identifying strategies to target the metabolic flexibility of tumours","volume":"2","author":"Mendez-Lucas","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.apsb.2021.09.022_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback activation of\u00a0leukemia inhibitory factor receptor limits response to histone\u00a0deacetylase inhibitors in breast cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.09.022_bib49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2021.09.022_bib50","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1038\/s41598-018-27303-6","article-title":"Mathematical modeling of the function of Warburg effect in tumor microenvironment","volume":"8","author":"Shamsi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.09.022_bib51","doi-asserted-by":"crossref","first-page":"1242454","DOI":"10.1126\/science.1242454","article-title":"Fueling immunity: insights into metabolism and lymphocyte function","volume":"342","author":"Pearce","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2021.09.022_bib52","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jconrel.2020.10.052","article-title":"Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity","volume":"329","author":"Zhao","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.09.022_bib53","doi-asserted-by":"crossref","first-page":"L1512","DOI":"10.1152\/ajplung.2001.281.6.L1512","article-title":"Albumin uptake and transcytosis in endothelial cells in\u00a0vivo induced by albumin-binding protein","volume":"281","author":"Vogel","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:15:36Z","timestamp":1762604136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2211383521003816"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.09.022","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remodeling \u201ccold\u201d tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}